-
ACE2–MasR–Sirt1 Signaling in Septic Cardiomyopathy
2026-09-24
A mouse study links reduced cardiac ACE2 during sepsis to impaired mitochondrial biogenesis and cardiac injury, and reports that pharmacological ACE2 activation with diminazene aceturate improved several disease-associated outcomes. The reciprocal inhibitor findings support a role for ACE2–MasR–Sirt1 signaling, while leaving important questions about mechanism, dosing, and clinical translation open.
-
Simulation-Guided LNP Size Control for mRNA Delivery
2026-09-24
The study uses computational fluid dynamics to guide microfluidic mixing and generate lipid nanoparticles across a controlled size range while holding lipid ratios constant. Its in vitro and in vivo results identify particle size as an important design variable for mRNA delivery, although the findings do not establish a universal optimal size or replace formulation-specific testing.
-
5X Protein Loading Buffer (Reducing) Guide
2026-09-23
5X Protein Loading Buffer (Reducing) prepares protein samples for conventional reducing SDS-PAGE by combining SDS, a sulfhydryl reducing agent, buffer salts, and a tracking dye. Use it when denaturation and disulfide-bond reduction are appropriate; do not use it for native analysis or workflows that need to preserve non-reduced disulfide patterns.
-
BFH772 (VEGFR2 inhibitor) Protocol Guide
2026-09-23
BFH772 is a selective small-molecule VEGFR2 kinase tool for testing VEGFR2-dependent signaling and angiogenesis in biochemical, cellular, and tumor-model workflows. It is suited to organic-solvent stock preparation but should not be selected for water-based formulations or interpreted as a broad-spectrum kinase inhibitor without additional counter-screening.
-
H2S, Persulfidation, and Ferroptosis in NSCLC
2026-09-22
A 2024 Molecular Cell study shows that hydrogen sulfide sensitizes non-small cell lung cancer cells to ferroptosis during cystine depletion by persulfidating S-adenosyl homocysteine hydrolase. This modification reduces homocysteine production, limits cysteine and glutathione availability, and provides a mechanistic rationale for combining hydrogen sulfide activity with ferroptosis-based therapies.
-
METTL16–SENP3–LTF Axis in HCC Ferroptosis
2026-09-22
Wang et al. identify a METTL16–SENP3–LTF signaling axis that protects hepatocellular carcinoma cells from iron-dependent lipid peroxidation and supports tumor progression. The study connects m6A-regulated RNA stability with SUMO-dependent protein turnover and iron sequestration, providing a mechanistic framework for sensitizing HCC to ferroptosis-based interventions.
-
Lisinopril Dihydrate: ACE Assay Interpretation
2026-09-21
Lisinopril dihydrate is a long-acting ACE inhibitor whose value in cardiovascular and renal models depends on interpreting direct enzyme inhibition alongside downstream renin–angiotensin readouts. This article presents an assay-centered framework, grounded in comparative peptidase evidence, for improving mechanistic confidence and reproducibility.
-
Carvedilol Phosphate: A New Lens on Hepatic IRI
2026-09-21
A translational strategy for using Carvedilol Phosphate as a defined adrenergic perturbation in hepatic ischemia–reperfusion studies, anchored to the Arrb2–6-ketoLCA–macrophage axis while separating established evidence from exploratory hypotheses.
-
CCK8, NOX4, and ANP Secretion in Rat Atria
2026-09-20
The reference study identifies a signaling mechanism by which sulfated cholecystokinin octapeptide stimulates ANP secretion in isolated beating rat atria. Its results connect fatty-acid signaling, NOX4-derived hydrogen peroxide, PGC-1α, and PPARα/PPARγ activation, while also revealing feedback regulation by ANP.
-
Saquinavir Workflows for HIV Protease Research
2026-09-19
Use Saquinavir as a controlled HIV protease inhibitor benchmark for enzymatic, cellular, and membrane-interaction studies. A biomimetic chromatography workflow helps separate target-enzyme activity from permeability behavior, supporting more informative antiretroviral drug research and exploratory cancer research.
-
Aminopeptidase Selectivity in ACE Inhibitor Studies
2026-09-18
Tieku and Hooper’s 1992 study directly compared inhibitor activity across aminopeptidases A, N, and W, revealing that commonly assumed selectivity patterns—especially for bestatin—were not reliable. The findings show why enzyme-panel controls are essential when interpreting ACE inhibitor experiments, peptide metabolism, and cardiovascular or renal disease models.
-
EZ Cap™ CBEmax mRNA: Fidelity-First Design
2026-09-18
EZ Cap™ CBEmax mRNA (m1Ψ) supports transient cytosine base-editing research, but meaningful results depend on guide selection, controls, and off-target analysis. This article translates whole-genome evidence into a practical assay framework distinct from embryo-production case studies.
-
Angiotensin I Workflows for RAS Research
2026-09-17
Build reproducible Angiotensin I conversion, cell-signaling, and drug-screening assays with practical controls for peptide stability and matrix effects. A data-quality framework inspired by fluorescence classification research helps separate genuine biological signals from analytical interference without overstating cross-domain evidence.
-
Angiotensin Peptides and SARS-CoV-2 Spike–AXL Binding
2026-09-17
Oliveira et al. report that selected naturally occurring angiotensin peptides enhance antibody-detected binding between the SARS-CoV-2 spike protein and AXL, with some shorter or N-terminally modified peptides showing greater activity than angiotensin II. The work provides a mechanistic link between renin-angiotensin signaling and viral receptor biology while emphasizing that binding enhancement must be distinguished from proven effects on infection or disease.
-
Angiotensin 1/2 (2-7) Research Workflows
2026-09-16
Use Angiotensin 1/2 (2-7) as a defined peptide input for renin-angiotensin signaling pathway studies, vascular-response assays, and receptor-binding experiments. Its short sequence also provides a practical bridge to emerging work on angiotensin-modulated SARS-CoV-2 spike–receptor interactions.